Comparison of gadodiamide-enhanced MR angiography to intraarterial digital subtraction angiography for evaluation of renal artery stenosis: Results of a phase III multicenter trial

Vesna D Garovic, Manuela A. Achauer, Thomas Kittner, David Horák, Rubin Sheng, Anthony W. Stanson

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: To evaluate the efficacy and safety of 0.1 mmol/kg gadodiamide administration for contrast-enhanced magnetic resonance angiography (MRA) in detecting hemodynamically relevant renal artery stenosis (RAS) when compared with intraarterial digital subtraction angiography (IA-DSA) as the gold standard. Materials and Methods: In a multicenter, controlled study, 395 patients with suspected or known RAS were included. Three independent readers evaluated the MRA images. Two readers evaluated the IA-DSA images and subsequently achieved consensus. The sensitivities and specificities of gadodiamide-enhanced MRA were analyzed at the per-patient and per-vessel levels (exact 1-sided binomial test at a α 0.025 with 95% confidence interval). Results: A total of 335 patients who had available standard of truth and MRA tests were included in the all-subjects efficacy population: 55.5% (186/335) men and 44.5% women with a mean age of 63 ± 13 years (range 17-85 years). The sensitivities and specificities ranged from 81% to 86% for all independent readers at the per-patient analysis based on subjects with the diagnostic images. Similar results were achieved with per-vessel level analysis. Fewer than 1% of patients had adverse event associated with gadodiamide administration. There were no cases of nephrogenic systemic fibrosis (NSF) reported. Conclusion: Gadodiamide administration at the labeled dose of 0.1 mmol/kg for contrast-enhanced MRA achieved equivalent results compared to IA-DSA in evaluation of RAS and was well tolerated.

Original languageEnglish (US)
Pages (from-to)390-397
Number of pages8
JournalJournal of Magnetic Resonance Imaging
Volume31
Issue number2
DOIs
StatePublished - Feb 2010

Fingerprint

gadodiamide
Renal Artery Obstruction
Digital Subtraction Angiography
Magnetic Resonance Angiography
Multicenter Studies
Angiography
Nephrogenic Fibrosing Dermopathy
Sensitivity and Specificity
Confidence Intervals
Safety

Keywords

  • Contrast-enhanced magnetic resonance angiography
  • Gadodiamide administration
  • Multicenter, controlled study
  • Renal artery stenosis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Comparison of gadodiamide-enhanced MR angiography to intraarterial digital subtraction angiography for evaluation of renal artery stenosis : Results of a phase III multicenter trial. / Garovic, Vesna D; Achauer, Manuela A.; Kittner, Thomas; Horák, David; Sheng, Rubin; Stanson, Anthony W.

In: Journal of Magnetic Resonance Imaging, Vol. 31, No. 2, 02.2010, p. 390-397.

Research output: Contribution to journalArticle

@article{a7eaac274861418ab4710326bf2374ab,
title = "Comparison of gadodiamide-enhanced MR angiography to intraarterial digital subtraction angiography for evaluation of renal artery stenosis: Results of a phase III multicenter trial",
abstract = "Purpose: To evaluate the efficacy and safety of 0.1 mmol/kg gadodiamide administration for contrast-enhanced magnetic resonance angiography (MRA) in detecting hemodynamically relevant renal artery stenosis (RAS) when compared with intraarterial digital subtraction angiography (IA-DSA) as the gold standard. Materials and Methods: In a multicenter, controlled study, 395 patients with suspected or known RAS were included. Three independent readers evaluated the MRA images. Two readers evaluated the IA-DSA images and subsequently achieved consensus. The sensitivities and specificities of gadodiamide-enhanced MRA were analyzed at the per-patient and per-vessel levels (exact 1-sided binomial test at a α 0.025 with 95{\%} confidence interval). Results: A total of 335 patients who had available standard of truth and MRA tests were included in the all-subjects efficacy population: 55.5{\%} (186/335) men and 44.5{\%} women with a mean age of 63 ± 13 years (range 17-85 years). The sensitivities and specificities ranged from 81{\%} to 86{\%} for all independent readers at the per-patient analysis based on subjects with the diagnostic images. Similar results were achieved with per-vessel level analysis. Fewer than 1{\%} of patients had adverse event associated with gadodiamide administration. There were no cases of nephrogenic systemic fibrosis (NSF) reported. Conclusion: Gadodiamide administration at the labeled dose of 0.1 mmol/kg for contrast-enhanced MRA achieved equivalent results compared to IA-DSA in evaluation of RAS and was well tolerated.",
keywords = "Contrast-enhanced magnetic resonance angiography, Gadodiamide administration, Multicenter, controlled study, Renal artery stenosis",
author = "Garovic, {Vesna D} and Achauer, {Manuela A.} and Thomas Kittner and David Hor{\'a}k and Rubin Sheng and Stanson, {Anthony W.}",
year = "2010",
month = "2",
doi = "10.1002/jmri.22032",
language = "English (US)",
volume = "31",
pages = "390--397",
journal = "Journal of Magnetic Resonance Imaging",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Comparison of gadodiamide-enhanced MR angiography to intraarterial digital subtraction angiography for evaluation of renal artery stenosis

T2 - Results of a phase III multicenter trial

AU - Garovic, Vesna D

AU - Achauer, Manuela A.

AU - Kittner, Thomas

AU - Horák, David

AU - Sheng, Rubin

AU - Stanson, Anthony W.

PY - 2010/2

Y1 - 2010/2

N2 - Purpose: To evaluate the efficacy and safety of 0.1 mmol/kg gadodiamide administration for contrast-enhanced magnetic resonance angiography (MRA) in detecting hemodynamically relevant renal artery stenosis (RAS) when compared with intraarterial digital subtraction angiography (IA-DSA) as the gold standard. Materials and Methods: In a multicenter, controlled study, 395 patients with suspected or known RAS were included. Three independent readers evaluated the MRA images. Two readers evaluated the IA-DSA images and subsequently achieved consensus. The sensitivities and specificities of gadodiamide-enhanced MRA were analyzed at the per-patient and per-vessel levels (exact 1-sided binomial test at a α 0.025 with 95% confidence interval). Results: A total of 335 patients who had available standard of truth and MRA tests were included in the all-subjects efficacy population: 55.5% (186/335) men and 44.5% women with a mean age of 63 ± 13 years (range 17-85 years). The sensitivities and specificities ranged from 81% to 86% for all independent readers at the per-patient analysis based on subjects with the diagnostic images. Similar results were achieved with per-vessel level analysis. Fewer than 1% of patients had adverse event associated with gadodiamide administration. There were no cases of nephrogenic systemic fibrosis (NSF) reported. Conclusion: Gadodiamide administration at the labeled dose of 0.1 mmol/kg for contrast-enhanced MRA achieved equivalent results compared to IA-DSA in evaluation of RAS and was well tolerated.

AB - Purpose: To evaluate the efficacy and safety of 0.1 mmol/kg gadodiamide administration for contrast-enhanced magnetic resonance angiography (MRA) in detecting hemodynamically relevant renal artery stenosis (RAS) when compared with intraarterial digital subtraction angiography (IA-DSA) as the gold standard. Materials and Methods: In a multicenter, controlled study, 395 patients with suspected or known RAS were included. Three independent readers evaluated the MRA images. Two readers evaluated the IA-DSA images and subsequently achieved consensus. The sensitivities and specificities of gadodiamide-enhanced MRA were analyzed at the per-patient and per-vessel levels (exact 1-sided binomial test at a α 0.025 with 95% confidence interval). Results: A total of 335 patients who had available standard of truth and MRA tests were included in the all-subjects efficacy population: 55.5% (186/335) men and 44.5% women with a mean age of 63 ± 13 years (range 17-85 years). The sensitivities and specificities ranged from 81% to 86% for all independent readers at the per-patient analysis based on subjects with the diagnostic images. Similar results were achieved with per-vessel level analysis. Fewer than 1% of patients had adverse event associated with gadodiamide administration. There were no cases of nephrogenic systemic fibrosis (NSF) reported. Conclusion: Gadodiamide administration at the labeled dose of 0.1 mmol/kg for contrast-enhanced MRA achieved equivalent results compared to IA-DSA in evaluation of RAS and was well tolerated.

KW - Contrast-enhanced magnetic resonance angiography

KW - Gadodiamide administration

KW - Multicenter, controlled study

KW - Renal artery stenosis

UR - http://www.scopus.com/inward/record.url?scp=75749126180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749126180&partnerID=8YFLogxK

U2 - 10.1002/jmri.22032

DO - 10.1002/jmri.22032

M3 - Article

C2 - 20099352

AN - SCOPUS:75749126180

VL - 31

SP - 390

EP - 397

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

SN - 1053-1807

IS - 2

ER -